Bayer (BAYN) Given a €77.00 Price Target at Goldman Sachs Group

Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer (FRA:BAYN) in a research report sent to investors on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Several other equities research analysts also recently commented on BAYN. DZ Bank reiterated a neutral rating on shares of Bayer in a report on Friday, April 26th. Nord/LB set a €62.00 ($72.09) target price on Bayer and gave the company a neutral rating in a report on Thursday, April 25th. Sanford C. Bernstein set a €90.00 ($104.65) target price on Bayer and gave the company a buy rating in a report on Friday, April 12th. Deutsche Bank set a €70.00 ($81.40) price objective on Bayer and gave the stock a neutral rating in a report on Thursday, April 25th. Finally, Warburg Research set a €69.00 ($80.23) price objective on Bayer and gave the stock a neutral rating in a report on Thursday, April 25th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of €81.72 ($95.02).

Shares of FRA:BAYN opened at €61.57 ($71.59) on Monday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Backdoor Roth IRA Conversion and Strategy

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.